STOCK TITAN

Viridian Therapeutics (VRDN) Free Cash Flow by Year

VRDN NASDAQ

Viridian Therapeutics, Inc. recorded an outflow of $276.9M in free cash flow in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to an outflow of $343.4M in free cash flow. The table below carries 13 fiscal years, from 2013 to 2025, and the quarters Viridian Therapeutics, Inc. has filed alongside them.

FY2025 annual
Free Cash Flow -$276.9M
YoY n/m
5Y CAGR n/m
10Y CAGR n/m
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

VRDN Free Cash Flow by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-K
Free Cash Flow-$343.4M-$276.9Mn/m-$232.8Mn/m-$185.1Mn/m-$94.6Mn/m-$54.9Mn/m-$29.8Mn/m-$36.1Mn/m-$27.3Mn/m-$28.4Mn/m-$15.0Mn/m-$7.0Mn/m-$2.5Mn/m-$1.2M

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

VRDN Free Cash Flow by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Free Cash Flow-$93.1Mn/m-$106.6Mn/m-$119.7Mn/m-$24.0Mn/m-$84.7Mn/m-$75.4Mn/m-$92.7Mn/m-$73.4Mn/m-$68.0Mn/m-$46.2Mn/m-$45.2Mn/m-$38.0Mn/m

What free cash flow means

Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.

More Viridian Therapeutics, Inc. financials

Frequently Asked Questions

Viridian Therapeutics, Inc. recorded an outflow of $276.9M in free cash flow in fiscal year 2025.

Viridian Therapeutics, Inc. (VRDN) reported an outflow of $232.8M in free cash flow in fiscal year 2024 and an outflow of $276.9M in free cash flow in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Viridian Therapeutics, Inc. (VRDN) reported an outflow of $343.4M in free cash flow over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 13 fiscal years this page covers, Viridian Therapeutics, Inc. (VRDN) free cash flow went from -$1.2M in fiscal year 2013 to -$276.9M in fiscal year 2025.

Viridian Therapeutics, Inc. (VRDN) reported -$93.1M in free cash flow in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Viridian Therapeutics, Inc. (VRDN) reported on that line in every period on record.